Caplyta and Breastfeeding
Caplyta (lumateperone) passes into breast milk and should be used with caution during breastfeeding, requiring a careful risk-benefit discussion with your healthcare provider about whether to continue breastfeeding or discontinue the medication.
FDA Label Guidance
The FDA drug label for Caplyta explicitly states that lumateperone and its metabolites are present in human breast milk 1. In a clinical lactation study of 17 women, lumateperone was detected in breast milk with:
- Estimated daily infant dose: 0.0004 mg/kg/day
- Relative infant dose (RID): 0.06% of the maternal weight-adjusted dosage
- Several major circulating metabolites were also present in low amounts
- Aniline metabolites were not detectable in milk or maternal plasma
The label clearly advises: "Talk to your healthcare provider about the risks and benefits of breastfeeding and the best way to feed your baby during treatment with CAPLYTA" 1.
Key Clinical Considerations
What the Evidence Shows:
Drug transfer is low but present: While the RID of 0.06% is very low (generally, RIDs <10% are considered acceptable), there are no data on the effects of lumateperone on breastfed infants 1. The absence of safety data in infants is the critical concern here.
Unknown infant effects: The FDA label explicitly states "There are no data on the effects of lumateperone on the breastfed infant or the effects on milk production" 1. This lack of data, combined with the drug's mechanism as an atypical antipsychotic affecting multiple neurotransmitter systems, raises legitimate safety concerns.
Practical Decision-Making Algorithm:
If the mother requires Caplyta for severe psychiatric illness (schizophrenia or bipolar depression):
Prioritize maternal mental health: Untreated severe mental illness poses significant risks to both mother and infant
Consider breastfeeding with close infant monitoring for:
- Sedation or excessive drowsiness
- Poor feeding
- Developmental milestones
- Any unusual behaviors
Implement safety measures:
- Use the lowest effective dose
- Time feedings to occur when drug levels are lowest (though lumateperone's pharmacokinetics make this less practical)
- Have regular pediatric follow-up
If alternative treatments are viable:
- Consider switching to antipsychotics with more established breastfeeding safety data before delivery or during the postpartum period
- Discuss with a reproductive psychiatrist about medication alternatives
Common Pitfalls to Avoid:
- Don't assume "low RID = completely safe": The 0.06% RID is reassuring, but the complete absence of infant outcome data means we cannot definitively declare safety
- Don't make unilateral decisions: This requires shared decision-making between the patient, psychiatrist, and pediatrician
- Don't ignore maternal illness severity: The risks of untreated maternal psychiatric illness (including potential harm to the infant from an unstable mother) must be weighed against theoretical infant drug exposure risks
What We Don't Know:
The evidence is notably silent on long-term neurodevelopmental outcomes in breastfed infants exposed to lumateperone. Given that this is an atypical antipsychotic affecting serotonin, dopamine, and glutamate systems 2, and that infant brain development is ongoing during the breastfeeding period, caution is warranted despite the low milk transfer.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CAPLYTA and any potential adverse effects on the breastfed child 1. This is not a blanket contraindication, but rather a situation requiring careful individualized assessment with close monitoring if breastfeeding continues.